{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:02:01Z","timestamp":1790283721797,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Endocrinology & Metabolism"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.tem.2026.09.001","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:34:43Z","timestamp":1790282083000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current antiretrovirals, hyperglycemia, and type 2 diabetes in people with HIV"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7269-9960","authenticated-orcid":false,"given":"Megan","family":"Farminer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9795-549X","authenticated-orcid":false,"given":"V\u00e9ronique","family":"B\u00e9r\u00e9ziat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8256-9545","authenticated-orcid":false,"given":"Ghislaine","family":"Guillemain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6577-9009","authenticated-orcid":false,"given":"Bruno","family":"F\u00e8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0700-8286","authenticated-orcid":false,"given":"Claire","family":"Lagathu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1710-4186","authenticated-orcid":false,"given":"Jacqueline","family":"Capeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tem.2026.09.001_bb0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005153","article-title":"Adipose tissue is a neglected viral reservoir and an inflammatory site during chronic HIV and SIV infection","volume":"11","author":"Damouche","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.tem.2026.09.001_bb0010","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3390\/cells9040854","article-title":"SIV infection and the HIV proteins Tat and Nef induce senescence in adipose tissue and human adipose stem cells, resulting in adipocyte dysfunction","volume":"9","author":"Gorwood","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.tem.2026.09.001_bb0015","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.molmed.2010.03.002","article-title":"HIV-associated lipodystrophy: from fat injury to premature aging","volume":"16","author":"Caron-Debarle","year":"2010","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.tem.2026.09.001_bb0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41572-020-0181-1","article-title":"HIV and antiretroviral therapy-related fat alterations","volume":"6","author":"Koethe","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.tem.2026.09.001_bb0025","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/archinte.165.10.1179","article-title":"Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study","volume":"165","author":"Brown","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.tem.2026.09.001_bb0030","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/QAD.0b013e32834e8776","article-title":"Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment","volume":"26","author":"Capeau","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.tem.2026.09.001_bb0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11904-022-00642-w","article-title":"Diabetes in HIV: the link to weight gain","volume":"20","author":"Bailin","year":"2023","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"10.1016\/j.tem.2026.09.001_bb0040","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1097\/QAD.0000000000003348","article-title":"Trends in diabetes incidence and associated risk factors among people with HIV in the current treatment era","volume":"36","author":"Spieler","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.tem.2026.09.001_bb0045","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1086\/518619","article-title":"Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study","volume":"45","author":"Ledergerber","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tem.2026.09.001_bb0050","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc07-2013","article-title":"Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study","volume":"31","author":"De Wit","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tem.2026.09.001_bb0055","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1089\/aid.2020.0247","article-title":"Expanding the Finnish Diabetes Risk Score for Predicting Diabetes Incidence in People Living with HIV","volume":"37","author":"Galaviz","year":"2021","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.tem.2026.09.001_bb0060","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/QAI.0000000000001071","article-title":"Weight gain and incident diabetes among HIV-infected veterans initiating antiretroviral therapy compared with uninfected individuals","volume":"73","author":"Herrin","year":"2016","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.tem.2026.09.001_bb0065","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/QAD.0000000000003127","article-title":"Sex differences in type 2 diabetes mellitus prevalence among persons with HIV","volume":"36","author":"Birabaharan","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.tem.2026.09.001_bb0070","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002844","article-title":"Risk factors for incident diabetes in a cohort taking first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy","volume":"95","author":"Karamchand","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.tem.2026.09.001_bb0075","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/QAI.0000000000000647","article-title":"New-onset diabetes and antiretroviral treatments in HIV-infected adults in Thailand","volume":"69","author":"Riyaten","year":"2015","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.tem.2026.09.001_bb0080","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/EDE.0000000000000815","article-title":"Incidence and risk factors for prediabetes and diabetes mellitus among HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis","volume":"29","author":"Nansseu","year":"2018","journal-title":"Epidemiology"},{"key":"10.1016\/j.tem.2026.09.001_bb0085","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/cid\/ciae406","article-title":"Integrase strand transfer inhibitor-related changes in body mass index and risk of diabetes: a prospective study from the RESPOND cohort consortium","volume":"80","author":"Rupasinghe","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tem.2026.09.001_bb0090","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/14740338.2019.1644317","article-title":"Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment","volume":"18","author":"Lagathu","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.tem.2026.09.001_bb0095","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1186\/s12879-022-07485-1","article-title":"Insulin resistance in people living with HIV is associated with exposure to thymidine analogues and\/or didanosine and prior immunodeficiency","volume":"22","author":"Hogh","year":"2022","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.tem.2026.09.001_bb0100","article-title":"Mitochondrial DNA variation, antiretroviral therapy, and incidence of diabetes among men with and without HIV. Open Forum","volume":"13","author":"Cronin","year":"2026","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.tem.2026.09.001_bb0105","first-page":"383","article-title":"Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease","volume":"25","author":"Vigouroux","year":"1999","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.tem.2026.09.001_bb0110","first-page":"225","article-title":"Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART)","volume":"25","author":"Vigouroux","year":"1999","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.tem.2026.09.001_bb0115","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3390\/jpm12071087","article-title":"CYP3A and CYP2B6 genotype predicts glucose metabolism disorder among HIV patients on long-term efavirenz-based ART: a case-control study","volume":"12","author":"Tadesse","year":"2022","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.tem.2026.09.001_bb0120","doi-asserted-by":"crossref","first-page":"e3902","DOI":"10.1093\/cid\/ciaa1073","article-title":"CYP2B6 genotype and weight gain differences between dolutegravir and efavirenz","volume":"73","author":"Griesel","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tem.2026.09.001_bb0125","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/COH.0000000000000833","article-title":"Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV","volume":"19","author":"Capeau","year":"2024","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.tem.2026.09.001_bb0130","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tem.2026.09.001_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.116010","article-title":"Divergent effects of the antiretroviral drugs, dolutegravir, tenofovir alafenamide, and tenofovir disoproxil fumarate, on human adipocyte function","volume":"220","author":"Quesada-Lopez","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tem.2026.09.001_bb0140","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1093\/cid\/ciaa259","article-title":"The integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in human\/simian adipose tissue and human adipocytes","volume":"71","author":"Gorwood","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tem.2026.09.001_bb0145","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/25787489.2020.1848131","article-title":"Changes in central adipose tissue after switching to integrase inhibitors","volume":"21","author":"Debroy","year":"2020","journal-title":"HIV Res. Clin. Pract."},{"key":"10.1016\/j.tem.2026.09.001_bb0150","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/cid\/ciae191","article-title":"Antiretrovirals and weight change: weighing the evidence","volume":"79","author":"Wohl","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tem.2026.09.001_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2026.101744","article-title":"Severe hyperglycemia after initiation of long-acting cabotegravir in two antiretroviral treatment-controlled people with HIV","volume":"52","author":"Valin","year":"2026","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.tem.2026.09.001_bb0160","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1177\/0956462416675107","article-title":"Integrase strand transfer inhibitor-associated diabetes mellitus: a case report","volume":"28","author":"Fong","year":"2017","journal-title":"Int. J. STD AIDS"},{"key":"10.1016\/j.tem.2026.09.001_bb0165","first-page":"19","article-title":"Raltegravir-associated diabetic ketoacidosis in a patient with HIV infection: a case report","volume":"43","author":"Horikawa","year":"2018","journal-title":"Tokai J. Exp. Clin. Med."},{"key":"10.1016\/j.tem.2026.09.001_bb0170","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/jac\/dkx365","article-title":"Dolutegravir-induced hyperglycaemia in a patient living with HIV","volume":"73","author":"McLaughlin","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.tem.2026.09.001_bb0175","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1093\/ofid\/ofz360.418","article-title":"Acute onset diabetic ketoacidosis\/hyperosmolar hyperglycemic state in patients taking integrase strand transfer inhibitors","volume":"6","author":"Ntem-Mensah","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.tem.2026.09.001_bb0180","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1016\/S2352-3018(20)30042-4","article-title":"Dolutegravir-associated hyperglycaemia in patients with HIV","volume":"7","author":"Lamorde","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.tem.2026.09.001_bb0185","article-title":"Bictegravir-based antiretroviral therapy-associated accelerated hyperglycemia and diabetes mellitus. Open Forum","volume":"8","author":"Nolan","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.tem.2026.09.001_bb0190","first-page":"503","article-title":"Hyperglycemia after dolutegravir-based antiretroviral therapy","volume":"14","author":"Hailu","year":"2021","journal-title":"Int. Med. Case Rep. J."},{"key":"10.1016\/j.tem.2026.09.001_bb0195","article-title":"Experience of dolutegravir-based antiretroviral treatment and risks of diabetes mellitus","volume":"10","author":"Hirigo","year":"2022","journal-title":"SAGE Open Med. Case Rep."},{"key":"10.1016\/j.tem.2026.09.001_bb0200","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.aed.2025.09.010","article-title":"Reversible severe hyperglycemia without ketoacidosis after initiation of bictegravir-containing antiretroviral therapy","volume":"13","author":"Aurora","year":"2026","journal-title":"AACE Endocrinol. Diabetes"},{"key":"10.1016\/j.tem.2026.09.001_bb0205","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/dme.13264","article-title":"Ketosis-prone atypical diabetes in Cameroonian people with hyperglycaemic crisis: frequency, clinical and metabolic phenotypes","volume":"34","author":"Lontchi-Yimagou","year":"2017","journal-title":"Diabet. Med."},{"key":"10.1016\/j.tem.2026.09.001_bb0210","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00125-022-05666-w","article-title":"When therapeutic drugs lead to diabetes","volume":"65","author":"Feve","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.tem.2026.09.001_bb0215","doi-asserted-by":"crossref","first-page":"e2234","DOI":"10.1093\/cid\/ciaa1403","article-title":"Risk of incident diabetes mellitus, weight gain, and their relationships with integrase inhibitor-based initial antiretroviral therapy among persons with human immunodeficiency virus in the United States and Canada","volume":"73","author":"Rebeiro","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tem.2026.09.001_bb0220","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/QAD.0000000000002718","article-title":"Incident type 2 diabetes mellitus after initiation of common HIV antiretroviral drugs","volume":"35","author":"Hsu","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.tem.2026.09.001_bb0225","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1093\/cid\/ciac355","article-title":"Integrase strand transfer inhibitors are associated with incident diabetes mellitus in people with human immunodeficiency virus","volume":"75","author":"O\u2019halloran, J.A.","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tem.2026.09.001_bb0230","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/hiv.13698","article-title":"Increased incidence of diabetes in people living with HIV treated with first-line integrase strand transfer inhibitors: a French multicentre retrospective study","volume":"26","author":"Ursenbach","year":"2025","journal-title":"HIV Med."},{"key":"10.1016\/j.tem.2026.09.001_bb0235","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/QAI.0000000000002447","article-title":"Metabolic changes associated with the use of integrase strand transfer inhibitors among virally controlled women","volume":"85","author":"Summers","year":"2020","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.tem.2026.09.001_bb0240","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1097\/QAD.0000000000003548","article-title":"Incident diabetes in course of antiretroviral therapy","volume":"37","author":"Taramasso","year":"2023","journal-title":"AIDS"},{"key":"10.1016\/j.tem.2026.09.001_bb0245","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1097\/QAD.0000000000003954","article-title":"Association between switching to integrase strand transfer inhibitors and incident diabetes in people with HIV","volume":"38","author":"Hwang","year":"2024","journal-title":"AIDS"},{"key":"10.1016\/j.tem.2026.09.001_bb0250","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1016\/S2352-3018(25)00335-2","article-title":"Incident diabetes after switching to integrase strand transfer inhibitors in people with HIV in the USA and Canada: a cohort study","volume":"13","author":"Hwang","year":"2026","journal-title":"Lancet HIV"},{"key":"10.1016\/j.tem.2026.09.001_bb0255","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1016\/S2352-3018(25)00354-6","article-title":"Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE","volume":"13","author":"Kileel","year":"2026","journal-title":"Lancet HIV"},{"key":"10.1016\/j.tem.2026.09.001_bb0260","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1093\/jac\/dkaa330","article-title":"Incidence of diabetes in HIV-infected patients treated with first-line integrase strand transfer inhibitors: a French multicentre retrospective study","volume":"75","author":"Ursenbach","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.tem.2026.09.001_bb0265","doi-asserted-by":"crossref","DOI":"10.1177\/13596535211067600","article-title":"Tenofovir alafenamide fumarate","volume":"27","author":"Lee","year":"2022","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.tem.2026.09.001_bb0270","doi-asserted-by":"crossref","first-page":"e652","DOI":"10.1093\/cid\/ciac621","article-title":"Metabolic-related outcomes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in adults with human immunodeficiency virus (HIV): a multicenter prospective cohort study","volume":"76","author":"Martinez-Sanz","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tem.2026.09.001_bb0275","doi-asserted-by":"crossref","first-page":"e1003","DOI":"10.1093\/infdis\/jiaf304","article-title":"Mitochondrial DNA haplogroups, biomarkers of inflammation and immune activation, and risk of diabetes in veterans with and without human immunodeficiency virus","volume":"232","author":"Yan","year":"2025","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tem.2026.09.001_bb0280","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1093\/cid\/ciaa026","article-title":"African mitochondrial DNA haplogroup L2 is associated with slower decline of \u03b2-cell function and lower incidence of diabetes mellitus in non-Hispanic, Black women living with human immunodeficiency virus","volume":"71","author":"Sun","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tem.2026.09.001_bb0285","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/QAD.0000000000002771","article-title":"Mitochondrial DNA haplogroups and weight gain following switch to integrase strand transfer inhibitor-based antiretroviral therapy","volume":"35","author":"Erlandson","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.tem.2026.09.001_bb0290","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.70952","article-title":"Hepatitis C virus and type 2 diabetes: mechanisms, clinical impact, and post-DAA management","volume":"98","author":"Chang","year":"2026","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.tem.2026.09.001_bb0295","doi-asserted-by":"crossref","first-page":"188","DOI":"10.23736\/S0026-4806.20.07129-3","article-title":"Chronic hepatitis C infection induces cardiovascular disease and type 2 diabetes: mechanisms and management","volume":"112","author":"Nevola","year":"2021","journal-title":"Minerva Med."},{"key":"10.1016\/j.tem.2026.09.001_bb0300","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/jvh.13984","article-title":"The role of treatment of hepatitis C with direct-acting antiviral agents on glycaemic control in diabetic patients: an updated systematic review and meta-analysis","volume":"31","author":"Chen","year":"2024","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.tem.2026.09.001_bb0305","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/v18020239","article-title":"Effect of direct-acting antiviral therapy on glycemic control in patients with chronic hepatitis C and type 2 diabetes: a systematic review and meta-analysis","volume":"18","author":"Hu","year":"2026","journal-title":"Viruses"},{"key":"10.1016\/j.tem.2026.09.001_bb0310","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11892-018-1076-3","article-title":"Diabetes and HIV","volume":"18","author":"Noubissi","year":"2018","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.tem.2026.09.001_bb0315","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3851\/IMP3049","article-title":"Neither boosted la nor darunavir with emtricitabine\/tenofovir disoproxil fumarate increase insulin resistance in healthy volunteers: results from the STRIBILD-IR study","volume":"21","author":"Spinner","year":"2016","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.tem.2026.09.001_bb0320","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3851\/IMP3098","article-title":"An open-label, randomized study of the impact on insulin sensitivity, lipid profile and vascular inflammation by treatment with lopinavir\/ritonavir or raltegravir in HIV-negative male volunteers","volume":"22","author":"Randell","year":"2017","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.tem.2026.09.001_bb0325","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3390\/cells11111841","article-title":"Inhibition of adipose tissue beiging by HIV integrase inhibitors, dolutegravir and bictegravir, is associated with adipocyte hypertrophy, hypoxia, elevated fibrosis, and insulin resistance in simian adipose tissue and human adipocytes","volume":"11","author":"Ngono Ayissi","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.tem.2026.09.001_bb0330","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/jac\/dky507","article-title":"Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients","volume":"74","author":"Calza","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.tem.2026.09.001_bb0335","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/QAI.0000000000002655","article-title":"Brief report: improvement in metabolic health parameters at week 48 after switching from a tenofovir alafenamide-based 3- or 4-drug regimen to the 2-drug regimen of dolutegravir\/lamivudine: the TANGO study","volume":"87","author":"van Wyk","year":"2021","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.tem.2026.09.001_bb0340","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/QAD.0000000000004468","article-title":"Changes in cardiovascular and metabolic risk scores after switching to DOR\/3TC\/TDF, DTG\/3TC or BIC\/FTC\/TAF: results from a multicenter Italian cohort","volume":"40","author":"Ciccullo","year":"2026","journal-title":"AIDS"},{"key":"10.1016\/j.tem.2026.09.001_bb0345","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1097\/QAD.0000000000003289","article-title":"Relationship between weight gain and insulin resistance in people living with HIV switching to integrase strand transfer inhibitors-based regimens","volume":"36","author":"Milic","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.tem.2026.09.001_bb0350","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1016\/S2352-3018(25)00105-5","article-title":"Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial","volume":"12","author":"Ryan","year":"2025","journal-title":"Lancet HIV"},{"key":"10.1016\/j.tem.2026.09.001_bb0355","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/hiv.13644","article-title":"Improvement in insulin sensitivity after switching from an integrase inhibitor-based regimen to doravirine\/tenofovir disoproxil fumarate\/lamivudine in people with significant weight gain","volume":"25","author":"Calza","year":"2024","journal-title":"HIV Med."},{"key":"10.1016\/j.tem.2026.09.001_bb0360","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00815-24","article-title":"Efficacy, safety, and anti-inflammatory properties of the switch to a doravirine-based regimen among antiretroviral-experienced elderly people living with HIV-1: the DORAGE cohort","volume":"69","author":"Lazzaro","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tem.2026.09.001_bb0365","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/ciae374","article-title":"Effect of 2 forms of tenofovir on duodenal enterocytes-a hypothesis for different effect of tenofovir disoproxil fumarate and tenofovir alafenamide on body weight and plasma lipids","volume":"80","author":"Kauppinen","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tem.2026.09.001_bb0370","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12981-025-00800-1","article-title":"Dolutegravir-associated hyperglycemia: a narrative review","volume":"22","author":"Buzibye","year":"2025","journal-title":"AIDS Res. Ther."},{"key":"10.1016\/j.tem.2026.09.001_bb0375","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2024.1458700","article-title":"The role of magnesium in pancreatic beta-cell function and homeostasis","volume":"11","author":"Akimbekov","year":"2024","journal-title":"Front. Nutr."},{"key":"10.1016\/j.tem.2026.09.001_bb0380","doi-asserted-by":"crossref","first-page":"R98","DOI":"10.1093\/ejendo\/lvag076","article-title":"Magnesium as an endocrine modulator: physiological roles, clinical evidence, and therapeutic perspectives","volume":"194","author":"Palermo","year":"2026","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2026.09.001_bb0385","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/08971900251394121","article-title":"Intersecting burdens: type 2 diabetes diagnosis, risk, and pharmacological management among people living with HIV","volume":"39","author":"Arnold","year":"2026","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.tem.2026.09.001_bb0390","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S2213-8587(24)00150-5","article-title":"Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial","volume":"12","author":"Eckard","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.tem.2026.09.001_bb0395","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11904-026-00776-1","article-title":"Obesity and weight management in HIV: epidemiology, complications, and emerging treatments","volume":"23","author":"Pryke","year":"2026","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"10.1016\/j.tem.2026.09.001_bb0400","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/cid\/ciae151","article-title":"Glucagon-like peptide 1 receptor agonists promote weight loss among people with HIV","volume":"79","author":"Nguyen","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tem.2026.09.001_bb0405","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1055\/a-2737-6227","article-title":"The impact of semaglutide on weight loss and inflammation in people with HIV. an observational prospective study in Greek population","volume":"134","author":"Petrakis","year":"2026","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"10.1016\/j.tem.2026.09.001_bb0410","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/QAD.0000000000003791","article-title":"Weight loss associated with semaglutide treatment among people with HIV","volume":"38","author":"Haidar","year":"2024","journal-title":"AIDS"},{"key":"10.1016\/j.tem.2026.09.001_bb0415","doi-asserted-by":"crossref","first-page":"486","DOI":"10.68040\/2026342.486493","article-title":"CROI 2026: HIV comorbidities","volume":"34","author":"Sarkar","year":"2026","journal-title":"Top. Antivir. Med."},{"key":"10.1016\/j.tem.2026.09.001_bb0420","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3390\/healthcare9091125","article-title":"Weekly semaglutide vs. liraglutide efficacy profile: a network meta-analysis","volume":"9","author":"Alsugair","year":"2021","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.tem.2026.09.001_bb0425","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11892-021-01382-8","article-title":"Diabetes in people with HIV","volume":"21","author":"Sarkar","year":"2021","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.tem.2026.09.001_bb0430","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/QAI.0000000000003227","article-title":"Brief report: use and side effects of sodium-glucose transporter 2 inhibitors among us people with HIV with clinical indications","volume":"94","author":"Sise","year":"2023","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.tem.2026.09.001_bb0435","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1071\/SH22070","article-title":"Under-utilisation of cardioprotective glucose-lowering medication in diabetics living with HIV","volume":"19","author":"Butale","year":"2022","journal-title":"Sex. Health"},{"key":"10.1016\/j.tem.2026.09.001_bb0440","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1007\/s00125-022-05773-8","article-title":"SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits","volume":"65","author":"Marilly","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.tem.2026.09.001_bb0445","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/COH.0000000000000609","article-title":"Senotherapeutics for HIV and aging","volume":"15","author":"Szaniawski","year":"2020","journal-title":"Curr. Opin. HIV AIDS"}],"container-title":["Trends in Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276026002407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276026002407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:34:54Z","timestamp":1790282094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043276026002407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":89,"alternative-id":["S1043276026002407"],"URL":"https:\/\/doi.org\/10.1016\/j.tem.2026.09.001","relation":{},"ISSN":["1043-2760"],"issn-type":[{"value":"1043-2760","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current antiretrovirals, hyperglycemia, and type 2 diabetes in people with HIV","name":"articletitle","label":"Article Title"},{"value":"Trends in Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tem.2026.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}